Mechanisms of renal damage in plasma cell dyscrasias: An overview

Contributions to Nephrology

Volumn 153, Issue , 2007, Pages 66-86

  Merlini, Giampaolo ^a,b   Pozzi, Claudio ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c A MANZONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN;

FANCONI RENOTUBULAR SYNDROME; GLOMERULONEPHRITIS; HUMAN; IMMUNOLOGY; KIDNEY; KIDNEY DISEASE; PARAPROTEINEMIA; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; ULTRASTRUCTURE; WALDENSTROEM MACROGLOBULINEMIA;

FANCONI SYNDROME; GLOMERULONEPHRITIS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KIDNEY; KIDNEY DISEASES; PARAPROTEINEMIAS; WALDENSTROM MACROGLOBULINEMIA;

EID: 33751528222     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000096761     Document Type: Review

References (79)

1. Herrera GA: Renal manifestations of plasma cell dyscrasias: an appraisal from the patients' bed-side to the research laboratory. Ann Diagn Pathol 2000;4:174-200.
2. Pesce AJ, Clyne DH, Pollak VE, Kant SK, Foulkes EC, Selenke WM: Renal tubular interactions of proteins. Clin Biochem 1980;13:209-215.
3. Klassen RB, Allen PL, Batuman V, Crenshaw K, Hammond TG: Light chains are a ligand for megalin. J Appl Physiol 2005;98:257-263.
4. Solomon A, Weiss DT, Kattine AA: Nephrotoxic potential of Bence Jones proteins. N Engl J Med 1991;324:1845-1851.
5. Isaac J, Herrera GA: Cast nephropathy in a case of Waldenstrom's macroglobulinemia. Nephron 2002;91:512-515.
6. Sanders PW, Booker BB, Bishop JB, Cheung HC: Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins. J Clin Invest 1990;85:570-576.
7. Sanders PW, Booker BB: Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992;89:630-639.
8. Ying WZ, Sanders PW: Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein. Am J Pathol 2001;158:1859-1866.
9. Huang ZQ, Sanders PW: Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein. J Clin Invest 1997;99:732-736.
10. Huang ZQ, Sanders PW: Biochemical interaction between Tamm-Horsfall glycoprotein and Ig light chains in the pathogenesis of cast nephropathy. Lab Invest 1995;73:810-817.
11. Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, D'Agati VD: Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001;12:1482-1492.
12. Herrera GA, Joseph L, Gu X, Hough A, Barlogie B: Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 2004;128:875-879.
13. Winearls CG: Acute myeloma kidney. Kidney Int 1995;48:1347-1361.
14. Gu X, Herrera GA: Light-chain-mediated acute tubular interstitial nephritis: a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia. Arch Pathol Lab Med 2006;130:165-169.
15. Ganeval D, Rabian C, Guerin V, Pertuiset N, Landais P, Jungers P: Treatment of multiple myeloma with renal involvement. Adv Nephrol Necker Hosp 1992;21:347-370.
16. Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E: Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998;158:1889-1893.
17. Montseny JJ, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, Eladari D: Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrol Dial Transplant 1998;13:1438-1445.
18. Pasquali S, Casanova S, Zucchelli A, Zucchelli P: Long-term survival patients with acute and severe renal failure due to multiple myeloma. Clin Nephrol 1990;34:247-254.
19. MacKay K, Striker L, D'Amico G, Striker GE: Dysproteinemias and Paraproteinemias; in Tisher CC, Brenner BY (eds): Renal Pathology. Philadelphia, Lippincott, 1989, pp 1363-1416.
20. Merlini G, Bellotti V: Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-596.
21. Eulitz M, Weiss DT, Solomon A: Immunoglobulin heavy-chain-associated amyloidosis. Proc Natl Acad Sci USA 1990;87:6542-6546.
22. Yazaki M, Fushimi T, Tokuda T, Kametani F, Yamamoto K, Matsuda M, Shimojo H, Hoshii Y, Higuchi K, Ikeda S: A patient with severe renal amyloidosis associated with an immunoglobulin gamma-heavy chain fragment. Am J Kidney Dis 2004;43:e23-e28.
23. Mai HL, Sheikh-Hamad D, Herrera GA, Gu X, Truong LD: Immunoglobulin heavy chain can be amyloidogenic: morphologic characterization including immunoelectron microscopy. Am J Surg Pathol 2003;27:541-545.
24. Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA: The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V-L germ line gene use and clonal plasma cell burden. Blood 2001;98:714-720.
25. Perfetti V, Casarini S, Palladini G, Vignarelli MC, Klersy C, Diegoli M, Ascari E, Merlini G: Analysis of V lambda-J lambda expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambda III) as a new amyloid-associated germline gene segment. Blood 2002;100:948-953.
26. Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R: Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood 2003;101:3801-3808.
27. Stevens FJ: Four structural risk factors identify most fibril-forming kappa light chains. Amyloid 2000;7:200-211.
28. Hurle MR, Helms LR, Li L, Chan W, Wetzel R: A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci USA 1994;91:5446-5450.
29. Raffen R, Dieckman LJ, Szpunar M, Wunschl C, Pokkuluri PR, Dave P, Wilkins Stevens P, Cai X, Schiffer M, Stevens FJ: Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains. Protein Sci 1999;8:509-517.
30. Wall JS, Gupta V, Wilkerson M, Schell M, Loris R, Adams P, Solomon A, Stevens F, Dealwis C: Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four V(lambda)6 proteins. J Mol Recognit 2004;17:323-331.
31. Bellotti V, Mangione P, Merlini G: Review: immunoglobulin light chain amyloidosis - the arche-type of structural and pathogenic variability. J Struct Biol 2000;130:280-289.
32. Teng J, Russell WJ, Gu X, Cardelli J, Jones ML, Herrera GA: Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest 2004;84:440-451.
33. Keeling J, Teng J, Herrera GA: AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest 2004;84:1322-1338.
34. Isaac J, Kerby JD, Russell WJ, Dempsey SC, Sanders PW, Herrera GA: In vitro modulation of AL-amyloid formation by human mesangial cells exposed to amyloidogenic light chains. Amyloid 1998;5:238-246.
35. Keeling J, Herrera GA: Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage. Kidney Int 2005;68:1590-1603.
36. Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D, Kindy M: Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 2000;6:643-651.
37. Harris DL, King E, Ramsland PA, Edmundson AB: Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes. J Mol Recognit 2000;13:198-212.
38. Kyle RA, Gertz MA: Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.
39. Obici L, Perfetti V, Palladini G, Moratti R, Merlini G: Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005;1753:11-22.
40. Sezer O, Eucker J, Jakob C, Possinger K: Diagnosis and treatment of AL amyloidosis. Clin Nephrol 2000;53:417-423.
41. Nakamoto Y, Hamanaka S, Akihama T, Miura AB, Uesaka Y: Renal involvement patterns of amyloid nephropathy: a comparison with diabetic nephropathy. Clin Nephrol 1984;22:188-194.
42. Watanabe T, Saniter T: Morphological and clinical features of renal amyloidosis. Virchows Arch A Pathol Anat Histol 1975;366:125-135.
43. Dikman SH, Churg J, Kahn T: Morphologic and clinical correlates in renal amyloidosis. Hum Pathol 1981;12:160-169.
44. Nolting SF, Campbell WG, Jr: Subepithelial argyrophilic spicular structures in renal amyloidosis - an aid in diagnosis. Pathogenic considerations. Hum Pathol 1981;12:724-734.
45. Buxbaum J, Gallo G: Nonamyloidotic monoclonal immunoglobulin deposition disease - light-chain, heavy-chain, and light- and heavy-chain deposition diseases. Hematol Oncol Clin North Am 1999;13:1235-1248.
46. Randall RE, Williamson WC Jr, Mullinax F, Tung MY, Still WJ: Manifestations of systemic light chain deposition. Am J Med 1976;60:293-299.
47. Deret S, Chomilier J, Huang DB, Preud'homme JL, Stevens FJ, Aucouturier P: Molecular modeling of immunoglobulin light chains implicates hydrophobic residues in non-amyloid light chain deposition disease. Protein Eng 1997;10:1191-1197.
48. Kaplan B, Vidal R, Kumar A, Ghiso J, Frangione B, Gallo G: Amino-terminal identity of co-existent amyloid and non-amyloid immunoglobulin kappa light chain deposits. A human disease to study alterations of protein conformation. Clin Exp Immunol 1997;110:472-478.
49. Khurana R, Gillespie JR, Talapatra A, Minert LJ, Ionescu-Zanetti C, Millett I, Fink AL: Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. Biochemistry 2001;40:3525-3535.
50. Davis DP, Gallo G, Vogen SM, Dul JL, Sciarretta KL, Kumar A, Raffen R, Stevens FJ, Argon Y: Both the environment and somatic mutations govern the aggregation pathway of pathogenic immunoglobulin light chain. J Mol Biol 2001;313:1021-1034.
51. Zhu L, Herrera GA, Murphy-Ullrich JE, Huang ZQ, Sanders PW: Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor-beta. Am J Pathol 1995;147:375-385.
52. Turbat-Herrera EA, Isaac J, Sanders PW, Truong LD, Herrera GA: Integrated expression of glomerular extracellular matrix proteins and beta 1 integrins in monoclonal light chain-related renal diseases. Mod Pathol 1997;10:485-495.
53. Ronco PM, Alyanakian MA, Mougenot B, Aucouturier P: Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol 2001;12:1558-1565.
54. Striker LJ, Doi T, Elliot S, Striker GE: The contribution of glomerular mesangial cells to progressive glomerulosclerosis. Semin Nephrol 1989;9:318-328.
55. Pozzi C, D'Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, Quattrocchio G, Rollino C, Segagni S, Locatelli F: Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 2003;42:1154-1163.
56. Aucouturier P, Khamlichi AA, Touchard G, Justrabo E, Cogne M, Chauffert B, Martin F, Preud'homme JL: Brief report: heavy-chain deposition disease. N Engl J Med 1993;329:1389-1393.
57. Kambham N, Markowitz GS, Appel GB, Kleiner MJ, Aucouturier P, D'Agati VD: Heavy chain deposition disease: the disease spectrum. Am J Kidney Dis 1999;33:954-962.
58. Strom EH, Fogazzi GB, Banfi G, Pozzi C, Mihatsch MJ: Light chain deposition disease of the kidney. Morphological aspects in 24 patients. Virchows Arch 1994;425:271-280.
59. Jones D, Bhatia VK, Krausz T, Pinkus GS: Crystal-storing histiocytosis: a disorder occurring in plasmacytic tumors expressing immunoglobulin kappa light chain. Hum Pathol 1999;30:1441-1448.
60. Terashima K, Takahashi K, Kojima M, Imai Y, Tsuchida S, Migita S, Ebina S, Itoh C: Kappa-type light chain crystal storage histiocytosis. Acta Pathol Jpn 1978;28:111-138.
61. Lebeau A, Zeindl-Eberhart E, Muller EC, Muller-Hocker J, Jungblut PR, Emmerich B, Lohrs U: Generalized crystal-storing histiocytosis associated with monoclonal gammopathy: molecular analysis of a disorder with rapid clinical course and review of the literature. Blood 2002;100:1817-1827.
62. Rocca A, Khamlichi AA, Touchard G, Mougenot B, Ronco P, Denoroy L, Deret S, Preud'homme JL, Aucouturier P, Cogne M: Sequences of V kappa L subgroup light chains in Fanconi's syndrome. Light chain V region gene usage restriction and peculiarities in myeloma-associated Fanconi's syndrome. J Immunol 1995;155:3245-3252.
63. Deret S, Denoroy L, Lamarine M, Vidal R, Mougenot B, Frangione B, Stevens FJ, Ronco PM, Aucouturier P: Kappa light chain-associated Fanconi's syndrome: molecular analysis of monoclonal immunoglobulin light chains from patients with and without intracellular crystals. Protein Eng 1999;12:363-369.
64. Leboulleux M, Lelongt B, Mougenot B, Touchard G, Makdassi R, Rocca A, Noel LH, Ronco PM, Aucouturier P: Protease resistance and binding of Ig light chains in myeloma-associated tubulopathies. Kidney Int 1995;48:72-79.
65. Bridoux F, Sirac C, Hugue V, Decourt C, Thierry A, Quellard N, Abou-Ayache R, Goujon JM, Cogne M, Touchard G: Fanconi's syndrome induced by a monoclonal Vkappa3 light chain in Waldenstrom's macroglobulinemia. Am J Kidney Dis 2005;45:749-757.
66. Norden AG, Lapsley M, Lee PJ, Pusey CD, Scheinman SJ, Tam FW, Thakker Ry Unwin RJ, Wrong O: Glomerular protein sieving and implications for renal failure in Fanconi syndrome. Kidney Int 2001;60:1885-1892.
67. Ma CX, Lacy MQ, Rompala JF, Dispenzieri A, Rajkumar SV, Greipp PR, Fonseca R, Kyle RA, Gertz MA: Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood 2004;104:40-42.
68. Messiaen T, Deret S, Mougenot B, Bridoux F, Dequiedt P, Dion JJ, Makdassi R, Meeus F, Pourrat J, Touchard G, Vanhille P, Zaoui P, Aucouturier P, Ronco PM: Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine 2000;79:135-154.
69. Tarantino A, Campise M, Banfi G, Confalonieri R, Bucci A, Montoli A, Colasanti G, Damilano I, D'Amico G, Minetti L, et al: Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995;47:618-623.
70. D'Amico G, Fornasieri A: Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus. Am J Kidney Dis 1995;25:361-369.
71. Veltman GA, van Veen S, Kluin-Nelemans JC, Bruijn JA, van Es LA: Renal disease in Waldenstrom's macroglobulinaemia. Nephrol Dial Transplant 1997;12:1256-1259.
72. Morel-Maroger L, Basch A, Danon F, Verroust P, Richet G: Pathology of the kidney in Waldenstrom's macroglobulinemia. Study of sixteen cases. N Engl J Med 1970;283:123-129.
73. Papo T, Musset L, Bardin T, Bucki B, Jorgensen C, Dion E, Quillard A, de Gennes C, Sany J, Godeau P, Piette JC: Cryocrystalglobulinemia as a cause of systemic vasculopathy and widespread erosive arthropathy. Arthritis Rheum 1996;39:335-340.
74. Gilboa N, Durante D, Guggenheim S, Lacher J, Holman R, Schorr W, Garfield D, McIntosh RM: Immune deposit nephritis and single-component cryoglobulinemia associated with chronic lymphocytic leukemia. Evidence for a role of circulating IgG-anti-IgG immune complexes in the pathogenesis of the renal lesion. Nephron 1979;24:223-231.
75. Touchard G, Preud'homme JL, Aucouturier P, Giraud C, Gouet D, Yver L, Patte D: Nephrotic syndrome associated with chronic lymphocytic leukemia: an immunological and pathological study. Clin Nephrol 1989;31:107-116.
76. Ball NJ, Wickert W, Marx LH, Thaell JF: Crystalglobulinemia syndrome. A manifestation of multiple myeloma. Cancer 1993;71:1231-1234.
77. Fogo A, Qureshi N, Horn RG: Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy. Am J Kidney Dis 1993;22:367-377.
78. Nasr SH, Markowitz GS, Stokes MB, Seshan SV, Valderrama E, Appel GB, Aucouturier P, D'Agati VD: Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis. Kidney Int 2004;65:85-96.
79. Soares SM, Lager DJ, Leung N, Haugen EN, Fervenza FC: A proliferative glomerulonephritis secondary to a monoclonal IgA. Am J Kidney Dis 2006;47:342-349.